Intravenous Immunoglobulin (IVIg) Market Share, SWOT Analysis, Global Trends and Industry Forecast to 2023

Intravenous Immunoglobulin Market – Synopsis

Intravenous Immunoglobulin (IVIg), a compound comprising of immune proteins (globulins) is administered into the bloodstream to treat patients with the inefficient or damaged immune systems. IVIg suffices the required antibodies by the human body to fight out the immune deficiency, and the consequent infectious attacks. Immunodeficiency Disorder could be a hereditary issue (Primary disorders), or caused due to the exposure to infections, mainly through bodily fluids, along with the cancer drugs and chemotherapy, aging is one of the key risk factor too that could put someone at greater risk of a damaged immune system.

Market Research Future (MRFR) has recently published a study report giving out the complete market forecast up to 2023. In its analysis, MRFR asserts that the global Intravenous Immunoglobulin Market Growth growing further will reach USD 8337.2 Million by 2023, registering 5.9% CAGR during 2017 to 2023.

Get a Free Sample @ https://www.marketresearchfuture.com/sample_request/3137

The demand for IVIg therapies to treat acquired and primary immunodeficiency diseases are on a rise as it is considered as a highly effective and the only available treatment method. Besides, sedentary lifestyle habits such as consumption of saturated fats sugar and salt, high alcohol consumption and les physical activities are resulting in the prevalence of such diseases. The growing prevalence of lifestyle related health issues like antibody deficiency disorders and obesity will add to the market growth during the evaluation period.

Major Players:

·         Baxter

·         Abeona Therapeutics

·         BDI Pharma

·         China Biologic Products

·         Biotest AG

·         Grifols Inc

·         CSL Behring

Intravenous Immunoglobulin Market – Competitive Analysis

The global IVIg market is fiercely competitive with the presence of several large and small players operating in the market. These market players acquire promising companies to expand in the fast-growing markets, focusing on improving their market performance. The market structure is dynamic due to the acquisition of local manufactures by the multinational companies. Strategies like product innovations and technologies are creating strong investment opportunities for the market players.

Intravenous Immunoglobulin Market – Segments

·         Global Intravenous Immunoglobulin (IVIg) Market has been segmented on the basis of type which comprise IgA (sub segments- IgA1 and IgA2), IgD, IgE, IgG,.

·         On the basis of application it segmented into CIDP (Progressive, Recurrent, Monophasic), Hypogammaglobulinemia (sub segments- AGM1, AGM2, AGM3, AGM4, AGM5, AGM6), Multifocal Motor Neuropathy, Immunodeficiency diseases (sub segments- X-linked agammaglobulinemia (XLA), common variable immunodeficiency (CVID), severe combined immunodeficiency), Primary Humoral Immunodeficiency (Subsegments- B cell (antibody) deficiencies, T cell deficiencies, Combination B and T cell deficiencies, Defective phagocytes, Complement deficiencies, Unknown (idiopathic)), Myasthenia Gravis (Sub segments- generalized myasthenia gravis, ocular myasthenia gravis, Congenital myasthenia gravis, Transient neonatal myasthenia gravis), Guillain-Barre syndrome (Sub segments- Acute inflammatory demyelinating polyradiculoneuropathy (AIDP), Miller Fisher syndrome (MFS), Acute motor axonal neuropathy (AMAN)and acute motor-sensory axonal neuropathy (AMSAN)), Kawasaki disease, ITP (Sub segments- acute and chronic), and others.

Intravenous Immunoglobulin Market – Geographical Analysis

Globally, North America is the leading market for IVIg, accounting for the largest revenue pocket, followed by the Europe & Asia Pacific markets, respectively.  The US market backed by the high expenditure on healthcare is the largest contributor to the regional market growth. Moreover, increasing prevalence of immunodeficiency disorder and rising demand for treatment measures provide impetus to the market growth.

On the other hand, Europe, the world’s second-largest market for IVIg, is fostered by the high per capita income and robust healthcare penetration in the region. The strong market growth in the countries like Germany & France drives the regional market growth, large scale. Attributing to the increasing investment in healthcare and rising number of patients with immune system diseases, the market is projected to register a phenomenal CAGR during the forecast period.

Asia Pacific market for the Intravenous Immunoglobulin is expected to perceive an exponential growth. Owing to the huge population and the burgeoning medical treatment market, India & China drive the regional market growth. Vietnam, Thailand, and Malaysia among the other South East Asian countries are projected to contribute significantly to the regional market growth. With the growing Medical Tourism markets in India & Malaysia the APAC region will register a significant CAGR during the review period.